Trade Abbvie - ABBV CFD

Trading Conditions
Spread0.17
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.02629 %
(-$5.00)

Trade size with leverage ~ $20,000.00

Short position overnight funding adjustment ~ $19,000.00


-0.02629%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.004068 %
($0.77)

Trade size with leverage ~ $20,000.00

Short position overnight funding adjustment ~ $19,000.00


0.004068%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity0.65
Margin5%
Stock exchangeUnited States of America
Commission on trade0%
Key Stats
Prev. Close171.02
Open171.56
1-Year Change25.68%
Day's Range171.15 - 172.25

AbbVie Company profile

AbbVie Inc. is a research-based pharmaceutical company, specialising in the discovery and development of biopharmaceuticals and small molecule drugs. With a team of around 29,000 scientists, researchers, manufacturing specialists and communications professionals across the globe, the company introduces new approaches to treating chronic conditions and life-threatening health issues. In 2019, AbbVie was ranked 96th on the Fortune 500 list of America’s biggest companies. More than 30 million patients in over 170 countries are treated by AbbVie’s medicines annually. 

 

Headquartered in North Chicago, Illinois, AbbVie has 22 primary research and manufacturing facilities around the world. The company’s research centres are in the US, Germany and Japan; and its manufacturing sites are located in the USA, Puerto Rico, Ireland, Germany, Italy and Singapore.

 

The company produces medicines aimed at treating autoimmune diseases, cancers, viruses (including hepatitis C and HIV), neurological and metabolic disorders. According to the Wall Street Journal, in 2016, a specialty drug ibrutinib, retailed by the company, cost from $116,600 to $155,400 a year wholesale in the US. AbbVie estimates global sales of the drug at $5 billion in 2020.
 

The history of AbbVie started in 2013 when Abbott Laboratories split into two publicly traded companies. One, using the old company name, was to specialise in medical equipment and devices and nutritional products; the other, AbbVie, was to be a research-driven pharmaceutical manufacturer. From the start, AbbVie was interested in acquisitions: in 2014, it acquired ImmuVen for an undisclosed amount, and in 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers. 

 

Presently, the AbbVie share price is listed on the New York Stock Exchange (NYSE). It is also a constituent of both the S&P 100 and 500 indices. In 2018, AbbVie reported its annual revenues of over $32.75 billion. During the same year, the ABBV stock price hit an all-time high of $123. As of July 2019, the company’s market capitalisation was set at around $106.13 billion. 


Get the latest news on the Abbvie share price and stay on top of the ABBV share price chart with Capital.com.

 

Latest shares articles

Lloyds share price forecast: An attractive dividend stock?
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
13:36, 8 July 2024
Exterior of Infosys headquarters
Infosys shareholders: Who owns the most INFY stock?
Who are the major shareholders and decision-makers of Infosys?
07:12, 29 April 2024
Tesla logo atop of a Tesla Dealership illuminated at night.
Tesla shareholders: Who owns the most TSLA stock?
In this guide to Tesla’s ownership structure, we look at the biggest TSLA shareholders – both institutional and individual
08:00, 19 April 2024
US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co
The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.
14:43, 2 February 2024

Read our reviews to find out more about us

Read the feedback from our clients, whatever their experience level.

the simplicity and the pros of this app makes it amazing and a useful app

Hafsa

I have already tested many brokers and I can definitely say that Capital.com is the most professional trading tool.

PaCeKw

Capital.com is a good broker. I haven't had any problems with the trading platform but i qould advise that they add an option for either using lots or units.

Mr-phenom

I am in the first time but I look this website in YouTube there's a very good and safe platform for a traders Thinks for taking my opinion

MUHAMMAD JALIL MUHAMMAD ASGHAR

great UI, simple platform, low spreads, great coverage

Jihad Kattar

The videos are easy to follow, i get my profits and downs and understand the market now even more. This app is very well to understand. I would recommend this app to friends if they want to know.

Customer

Good and amazing app for trading and easy setups easy and smooth buy and sell amazing

QAISAR ALI

Excellent for people who would like to get and build all the experience needed to navigate to Stock Market.

Johnsy81

Overall my experience is very good with capital, the one best thing is they give you call support with most other broker apps don’t gives.

Ranjit

I have been usingCapital.comm platform for a year now. I did have some issues with using the platform in the earlier days but I received excellent support from Capital.com guiding me in the process of learning about the platform and put me on track. I am very happy with this platform and find it very easy to use for my trading needs. Capital.com also arranged a series of trading webinars last summer, which I attended and benefited from.

Dr Anjum Pervez

The best app for trade ever I tried to much trade app and this is the best

Moamen

Great website, easy to use and user friendly. Lot of markets to trade with. Good database of information and learning tutorials for beginner. Great customer support. I had some issues and they helped me solve them rapidly. One of the best broker, I recommend.

Nicolas Crampet

Trusted trading Platform Capital.com is the most trusted trading platform I ever experienced. Even without taking any demo,I have started funding and it’s going well. It is a very easy platform for the beginners and can have better trading experience by using this

JEYAKUMAR

great app, love the weekly and monthly insights, and review they send about my trading habits. spread for gold is usually 0.3 but at times fluctuates up to 0.9 this often makes it hard trading on the low time frames and not losing my position to spread even if my bias was correct, if the spread was better I'd give 5 star.

chris hoeben

Capital.com is the best broker of all time and I Should give it five stars but there is a small issue about execution of my orders through traddingview it is a bit slow. But the execution of orders directly from the capital.com App or Website is absolutely fast and apart from that everything is simple incredible.

IKOFO MOISE

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading